NASDAQ$SKIN
SkinHealth Systems Inc · Q2 2024 earnings
Q2 2024 earnings · · Investor relations
Briefing
Reported net sales of $90.6 million and year-over-year operating expense improvement of nearly $18 million or 22%.
BeautyHealth's Q2 2024 results showed net sales of $90.6 million, a decrease of (22.9)% compared to the same period in 2023. This was due to lower equipment sales, partially offset by growth in consumables net sales. The company is addressing these challenges by offering lower-priced device options and additional financing solutions to providers.
- Net sales were $90.6 million, a decrease of (22.9)% compared to Q2 2023, attributed to lower delivery systems net sales.
- Gross margin was 45.2% compared to 57.8% in Q2 2023, with adjusted gross margin at 49.4% compared to 64.5% in Q2 2023, impacted by higher inventory related charges.
- Net income was $0.2 million compared to $3.4 million in Q2 2023, primarily due to the gain on repurchase of convertible senior notes, partially offset by inventory related charges.
- Adjusted EBITDA loss was $(5.2) million compared to adjusted EBITDA of $12.4 million in Q2 2023, mainly due to inventory related charges and lower net sales.
Headline financials
Revenue & EPS history
Beauty Health · Revenue · Quarterly
$90.6M
Revenue by segment
Beauty Health · $97.4M total across 2 segments · Q3 2023
- Delivery Systems$51M+3.9%52.4%
- Consumables$46.4M+16.9%47.6%
Forward guidance
The company provided revised financial guidance for the third quarter and fiscal year 2024, reflecting continued pressure on delivery systems sales. It assumes no material deterioration in general market conditions and excludes any unannounced acquisitions, dispositions, or financings.
Headwinds
- Third quarter net sales are expected to be between $70 million and $80 million.
- Third quarter adjusted EBITDA is projected to be between ($6) million and ($1) million.
- Fiscal year 2024 net sales are anticipated to be between $325 million and $345 million.
- Fiscal year 2024 adjusted EBITDA is expected to be between ($10) million and $0 million.
- Financial guidance reflects continued pressure on delivery systems sales.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q2 2024
+0.6%
Avg return
Earnings day
-0.5%
Avg return
5 days after
-1.9%
Avg return
30 days after
52%
12 / 23 earnings
Positive
+52.1%
Q1 2025
Best reaction
-61.4%
Q3 2023
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | -2.5% | -29.9% | -34.9% | |
| Q4 2025 | +19.8% | +11.3% | -15.3% | |
| Q3 2025 | +8.7% | +3.1% | +13.2% | |
| Q1 2025 | +52.1% | +19.4% | +29.0% | |
| Q4 2024 | -5.6% | -9.9% | -26.1% | |
| Q3 2024 | +5.1% | -13.1% | -14.2% | |
| Q2 2024 | -10.4% | +0.8% | +12.8% | |
| Q1 2024 | -20.1% | -18.4% | -39.9% | |
| Q4 2023 | +16.8% | -0.8% | +4.4% | |
| Q3 2023 | -61.4% | -37.2% | -14.7% | |
| Q2 2023 | -6.0% | -12.9% | -24.2% | |
| Q1 2023 | -2.8% | -0.2% | -20.8% | |
| Q4 2022 | +8.7% | +13.5% | +7.4% | |
| Q3 2022 | -25.3% | -12.3% | -4.1% | |
| Q2 2022 | -8.3% | -8.8% | -18.5% | |
| Q1 2022 | -5.4% | +6.6% | +8.9% | |
| Q4 2019 | +4.0% | -4.1% | -12.9% | |
| Q4 2021 | +23.4% | +43.1% | +27.6% | |
| Q3 2021 | -11.9% | -8.0% | -13.9% | |
| Q2 2020 | +8.2% | +7.4% | +26.8% | |
| Q2 2021 | +10.6% | +23.9% | +30.3% | |
| Q1 2021 | +12.8% | +15.9% | +44.7% | |
| Q4 2020 | +2.8% | -0.9% | -10.0% | |
| Q3 2020 | — | — | — | |
| Q1 2020 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro